Risankizumab は乾癬性関節炎の健康関連の生活の質, 疼痛, 労働生産性を改善: KEEPsAKE 1
Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keac342
In this study risankizumab treatment resulted in greater improvements in fatigue and pain than placebo. Prior to this finding the study aimed to evaluate the impact of risankizumab on HRQoL and other PROs among patients with active PsA and inadequate response or intolerance to csDMARD-IR in the KEEPsAKE 1 trial.